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Abstract
Background: Pancreatic cancer accounts for about 220,000
deaths each year. Known risk factors are smoking and type 2
diabetes. It remains to be seen whether these risk factors are
equally important in Asia and whether other modifiable risk
factors have important associations with pancreatic cancer.
Methods: An individual participant data analysis of 30 cohort
studies was carried out, involving 420,310 Asian participants
(33% female) and 99,333 from Australia/New Zealand (45%
female). Cox proportional hazard models, stratified by study
and sex and adjusted for age, were used to quantify risk
factors for death from pancreatic cancer.
Results: During 3,558,733 person-years of follow-up, there
were 324 deaths from pancreatic cancer (54% Asia and 33%
female). Mortality rates (per 100,000 person-years) from
pancreatic cancer were 10 for men and 8 for women. The
following are age-adjusted hazard ratios (95% confidence
interval) for death from pancreatic cancer: for current
smoking, 1.61 (1.12-2.32); for diabetes, 1.76 (1.15-2.69); for a
2-cm increase in waist circumference, 1.08 (1.02-1.14). All
three relationships remained significant (P < 0.05) after
adjustment for other risk factors. There was no evidence of
heterogeneity in the strength of these associations between
either cohorts from Asia and Australia/New Zealand or
between the sexes. In men, the combination of cigarette
smoking and diabetes more than doubled the likelihood of
pancreatic cancer (2.47; 95% confidence interval, 1.17-5.21) in
both regions.
Conclusions: Smoking, obesity, and diabetes are important
and are potentially modifiable risk factors for pancreatic
cancer in populations of the Asia-Pacific region. Activities to
prevent them can be expected to lead to a major reduction in
the number of deaths from this cancer, particularly in Asia
with its enormous population. (Cancer Epidemiol Bio-
markers Prev 2006;15(12):2435–40)
Introduction
Worldwide, pancreatic cancer accounts for about 220,000
deaths annually and is the sixth major cause of cancer-related
mortality due to its very low 5-year survival; <5% in some
instances (1, 2). Increasing age is strongly associated with
elevations in the risk of pancreatic cancer, with <10% of cases
occurring in individuals <50 years of age (2). Modifiable
conditions, such as cigarette smoking, which is suggested to
explain one quarter of cases (3), and type 2 diabetes (4), are
widely accepted as risk factors for pancreatic cancer. However,
it is unclear whether other factors may also have important
associations with the disease. For example, some studies have
found obesity to be a risk factor independent of its effects on
diabetes (4-6). In addition, a recent meta-analysis (7) of
prospective cohorts concluded that there was a positive, but
weak, association between body mass index (BMI) and
pancreatic cancer risk, such that a 1-unit increment in BMI
was associated with a 2% increase in risk of pancreatic cancer.
There is also a small body of literature suggesting associations
between both blood pressure (8-10) and cholesterol (11-13)
with the risk of cancer.
To date, most of the prospective studies that have
investigated the environmental and physiologic determinants
of pancreatic cancer have been conducted in American (6) or
European (5) populations. By comparison, there are relatively
few studies examining the role of putative risk factors in
the etiology of the disease in Asian populations (14). This is
of importance given the recent substantial increases in the
prevalence of cigarette smoking (15), type 2 diabetes (16), and
obesity (17) in this highly populous region.
The Asia Pacific Cohort Studies Collaboration (18) com-
prises a large number of prospective cohort studies in the
region and was established to provide reliable evidence about
the relationships between a variety of modifiable risk factors
and the incidence of major causes of death among populations
in this region. The aims of this study were 2-fold: (a) to
investigate the associations between putative risk factors and
the risk of pancreatic cancer and (b) to estimate the burden of
the disease due to any important and modifiable risk factor in
two ethnically diverse populations of the Asia-Pacific Region,
China, and Australia.
Materials and Methods
Details of study identification, data collection, and event
verification in the Asia Pacific Cohort Studies Collaboration
are described elsewhere (18-24). Briefly, studies were included
if they had continued follow-up for at least 5,000 person-years
and had recorded vital status at the end of follow-up. Studies
were excluded if entry was dependent upon a particular
condition or risk factor. Mortality was classified according to
the 9th Revision of the International Classification of Diseases :
Pancreatic cancer was selected as ICD 157. Studies were
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classified as Asian if their participants were recruited from
Mainland China, Hong Kong, Japan, Korea, Singapore,
Taiwan, or Thailand and Australia/New Zealand (ANZ) if
from Australia or New Zealand.
All data on cigarette smoking (19)were based on self-report at
the time of entry into one of the included studies; smoking status
was recorded as current, former, or never smoker. Eighteen
studies additionally recorded the average number of cigarettes
per day for smokers; groups of <20 and z20 cigarettes were
chosen as 20 cigarettes corresponds to one standard pack.
Within most studies in the Asia Pacific Cohort Studies
Collaboration, there was no differentiation made between type
1 and type 2 diabetes; hence, the analyses included all
individuals with diabetes recorded at study baseline based
on either self-report (20) or an oral glucose tolerance test
(ref. 21; 86% of the total study population), or both. Using the
values for height and weight measured at study baseline, BMI
(22) was computed as weight in kilograms divided by height
squared (kg/m2). Some studies additionally recorded waist
circumference (cm). At recruitment, data were also collected
on current medications and several risk factors, including
blood pressure (23) and cholesterol (24).
Analyses used individual participant data and were
restricted to individuals ages z20 years at enrollment. Cox
proportional hazard models, stratified by study and sex and
adjusted for age, were used to estimate hazard ratios (HR) and
95% confidence interval (95% CI) associated with putative risk
factors both before and after adjustment for other risk factors.
Associations between continuously distributed variables and
pancreatic cancer were assessed by obtaining the HRs and 95%
CIs for a standard increment in each variable. Dose-response
associations were explored by categorizing study participants
into equal tertiles of continuous distributions. Due to the
limited number of events among the studies that had
information on waist circumference, we did not examine the
dose-response association between waist circumference and
pancreatic cancer but instead examined the relationship with
waist circumference as a continuous variable. Tests for
regional and sex interactions were conducted by adding
interaction terms to the Cox model.
Within prospective cohorts, values for risk factors measured
at study baseline will fluctuate due to several factors, including
measurement error or within-person variability, resulting in an
underestimation of the true association with disease risk,
which is termed regression dilution bias (25). By using repeat
measurements of the risk factors from a sample of the total
study population, attenuation coefficients were derived using
a linear regression model that accounted for the heterogeneity
of variance between studies, within-subject correlation, and the
varying time intervals between measurements (25). Informa-
tion on repeat measures of blood pressure, total cholesterol,
BMI, waist circumference, and fasting glucose were available
on up to 16 studies for between one to seven occasions with a
median between 3 and 29 years after the baseline measure-
ment. Regression attenuation coefficients were calculated in
this way for total cholesterol (1.7), systolic blood pressure (1.9),
diastolic blood pressure (2.1), fasting glucose (1.6), BMI (1.2),
and waist circumference (1.4).
The excess risk of pancreatic cancer associated with being a
current smoker and having diabetes was examined by creating
dummy variables in a multivariate model and testing for effect
modification by introducing interaction terms. The population
attributable risks for mortality from pancreatic cancer associ-
ated with risk factors were calculated separately for Australia
and China, using previously published prevalence estimates of
the prevalence of smoking (15, 26) and type 2 diabetes (27, 28)
and the formula:
Results
The characteristics of the participants in the 30 cohort studies
within the Asia Pacific Cohort Studies Collaboration that
contributed to these analyses are summarized in Table 1. In
total, 182,173 (35% female) individuals with a median follow-
up of 6.9 years and a mean age of 47 years were included in the
analysis. The mean prevalence of diabetes was similar among
cohorts from Asia and ANZ (6.6% and 5%, respectively),
whereas the prevalence of current smoking and mean BMI
varied substantially within, and between, the two regions
(Table 1).
Overall, there were 324 deaths from pancreatic cancer
(54% Asia and 33% female) during 3,558,733 person-years of
follow-up, although the actual number of deaths included in
each analysis of risk factors varied according to the availability
of information for each risk factor (Table 2). In both Asia and
ANZ, mortality rates from pancreatic cancer were higher in
men than in women (7 versus 5 per 100,000 person-years
among men and women in Asia, respectively); in ANZ, the
corresponding rates were 19 and 13 per 100,000 person-years,
respectively. Statistical heterogeneity by sex and region was
examined by adding interaction terms for sex and region in the
Cox model.
Age and Pancreatic Cancer. The risk of pancreatic cancer
was strongly associated with age. Among individuals over the
age of 75 years, the risk of developing the neoplasm was 14
times higher compared with those <55 years of age (HR, 13.9;
95% CI, 7.06-27.4). The association was approximately linear in
that for every extra 10 years of increase in age, the risk of
pancreatic cancer more than doubled (HR, 2.55; 95% CI, 2.16-
2.97). There was no evidence of heterogeneity in the strength
of the association between men and women or between Asia
and ANZ cohorts (P > 0.8 for both).
Cigarette Smoking and Pancreatic Cancer. In age-adjusted
analyses, after exclusion of former smokers, current smokers
had a 60% increased risk of pancreatic cancer compared
with never smokers (HR, 1.61; 95% CI, 1.12-2.32), which was
unaffected by adjustment for diabetes and BMI. There was
good evidence of a dose-response association (Table 2) such
that for every five cigarettes smoked per day, the risk of
mortality from pancreatic cancer increased by 10% (P = 0.03;
Fig. 1). There was no difference in the strength of the
association between Asia and ANZ cohorts (P = 0.94) or
between men and women (P = 0.14).
Blood Glucose, Diabetes, and Pancreatic Cancer. Individ-
uals with diabetes had a 75% greater risk of pancreatic cancer
compared with individuals without diabetes (HR, 1.76; 95% CI,
1.15-2.69), which remained largely unchanged after adjustment
for smoking and BMI (HR, 1.78; 95% CI, 1.16-2.73). There was
no evidence of any regional or sex differences in the strength of
the observed relationship (P > 0.3 for both). To preclude the
possibility of reverse causality (i.e., pancreatic cancer causing
diabetes), the analyses were repeated after excluding the first
5 years of follow-up, which resulted in little change in the
HR (HR, 1.75; 95% CI, 0.87-3.55). Based on a small subgroup of
individuals with information on blood glucose, there was a
statistically significant dose-response relationship between
blood glucose and the risk of pancreatic cancer such that a
1 mmol/L higher blood glucose was associated with an
11% greater risk of mortality from pancreatic cancer (Fig. 1).
Body Anthropometry and Pancreatic Cancer. BMI was not
associated with mortality from pancreatic cancer in this cohort
(Fig. 1), but there was some evidence of a positive association
with central obesity, such that a 2-cm higher waist circumfer-
ence was associated with an 8% (95% CI, 2-15%) greater risk of
pancreatic cancer. The association was independent of the
potential confounding effects of diabetes and smoking, with no
PAR ¼ P ðRR 1Þ
1þ P ðRR 1Þ :
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evidence of regional or sex differences (P > 0.2 for both). There
was also some evidence to suggest that there was a positive
association between height with mortality from pancreatic
cancer: a 5-cm greater height was associated with a 9% greater
risk of death from pancreatic cancer (P = 0.14).
Total Cholesterol and Pancreatic Cancer. Although the
association between total cholesterol and mortality from
pancreatic cancer was not statistically significant (P = 0.29),
examination of the dose-response relationship suggests a weak
inverse relationship between total cholesterol and risk of
pancreatic cancer: individuals in the top tertile of blood
cholesterol had about a 25% lower risk of mortality from
pancreatic cancer than those in the lowest tertile (Table 2).
Because of the possibility of reverse causality, we excluded
those individuals who died from pancreatic cancer within the
first 5 years of follow-up, but it had no material effect on the
association. We also found no evidence of regional or sex
differences in the strength of the associations (P > 0.4 for both).
Blood Pressure, Antihypertensive Medication, and Pan-
creatic Cancer. There was no evidence of an association
between blood pressure and pancreatic cancer (Fig. 1). Based
on a subsample of individuals, among whom there were 130
deaths, a borderline statistically significant positive association
was observed between the use of antihypertensive medication
and mortality from pancreatic cancer. Individuals who were
receiving blood pressure lowering treatment at study baseline
had a 50% greater risk compared with those who were not on
antihypertensive treatment (HR, 1.46; 95% CI, 0.98-2.19). This
association was little altered by adjustment for cigarette
smoking, BMI, diabetes, or blood pressure. There was no
evidence of heterogeneity between regions or by sex (P > 0.10
for both).
Contribution of Modifiable Risk Factors to Mortality from
Pancreatic Cancer. In the current analyses, the combination of
cigarette smoking and diabetes more than doubled the
likelihood of mortality from pancreatic cancer in both regions
(HR, 2.47; 95% CI, 1.17-5.21). The contribution of cigarette
smoking and diabetes to mortality from pancreatic cancer
differed substantially between the sexes and between China
and Australia, assuming cause and effect (Table 3).
Discussion
The present study confirms the important etiologic role of
cigarette smoking and diabetes in pancreatic cancer found in
Western populations and extends these findings to Asian
populations. Moreover, it provides some support for central
obesity, as opposed to BMI, being an independent risk factor
for the disease. The principal strengths of the current study are
its large amount of individual participant data, over three
quarters of which are derived from Asian populations, and its
prospective design, and that more than three quarters of the
data included in the analyses are derived from Asian
populations, where data on risk factors for pancreatic cancer
are more limited.
As with previous studies (29-32), we observed a significant
dose-response relationship between cigarette smoking and
pancreatic cancer. We were unable to exclude the possibility of
Table 1. Study characteristics at baseline
Country Study Baseline No.
subjects
Mean
age (y)
Female
(%)
Diabetes
(%)
Median
FU (y)
PC
Deaths
Current
smokers (%)
Mean
CPD
Mean
BMI
M F M F
Australia Busselton 1966-1981 7,767 44.9 52 3.5 26.5 32 44 24 19 16 24.6
Australia Canberra-Queanbeyan 1990-1991 706 76.5 45 6.7 9.8 2 12 9 — — —
Australia Long. Study of Aging 1992-1993 1,610 78.1 48 8.3 4.6 1 8 8 16 13 26.0
Australia Melbourne 1990-1994 41,285 54.8 59 5.4 8.5 52 15 9 22 16 26.9
Australia National Heart
Foundation
1989-1990 9,277 43.5 51 1.9 8.3 9 27 21 21 16 25.4
Australia Newcastle 1983-1994 5,929 51.7 50 3.5 8.9 10 28 18 20 18 26.7
Australia Perth 1978-1994 10,230 45.1 48 2.1 14.4 22 30 21 20 16 25.2
Australia WA AAA Screenees 1996-1999 12,203 72.2 0 11.6 3.2 15 11 — 14 — 26.9
NZ Fletcher Challenge 1992-1994 10,326 44.3 28 2.6 5.8 7 25 18 15 13 26.4
ANZ Subtotal 1966-1999 99,333 53.4 45 5.0 8.3 150 20 14 20 16 26.3
China Anzhen 1991 8,378 53.8 55 — 4.3 5 51 10 15 10 23.9
China East Beijing 1977-1994 1,128 43.8 51 5.6 17.1 1 47 11 — — 23.6
China Guangzhou
Occupational
1985-1998 166,695 41.5 22 10.5 7.3 25 60 1 15 12 22.6
China Seven Cities Cohorts 1987 10,811 53.9 55 1.2 2.7 5 57 17 — — 22.6
China Six Cohorts 1982-1986 19,387 44.7 47 — 9.0 9 76 12 — — 21.2
China Tianjin 1984 9,335 54.6 51 — 6.1 4 63 39 — — 23.5
China Xi’an 1976 1,695 44.4 34 — 19.7 4 54 12 14 9 —
Hong Kong Hong Kong 1985-1991 2,983 78.6 57 8.6 2.5 3 29 11 13 8 21.9
Japan Aita town 1980-1983 1,130 50.8 59 2.7 16.4 3 66 2 22 13 22.6
Japan Akabane 1985-1986 1,834 54.5 56 2.5 11.0 6 62 1 23 9 22.5
Japan Civil Service Workers 1990-1992 9,240 46.7 33 1.8 6.7 2 51 11 — — 22.5
Japan Hisayama 1961 1,601 56.1 56 — 24.6 23 76 17 — — 21.6
Japan Konan 1987-1995 1,226 51.7 55 12.6 6.4 4 62 5 22 11 21.9
Japan Ohasama 1992-1993 2,240 59.5 64 10.9 4.1 2 51 2 — — 23.3
Japan Saitama 1986-1990 3,615 54.5 62 1.7 11.0 6 63 8 22 13 22.4
Japan Shibata 1977 2,350 56.9 58 1.1 20.0 14 72 4 20 10 22.4
Japan Shigaraki Town 1991-1997 3,730 57.1 59 7.2 4.4 2 59 8 22 13 22.5
Japan Shirakawa 1974-1979 4,640 48.0 54 1.0 17.5 15 70 5 — — 21.5
Singapore Singapore Heart 1982-1997 2,321 40.7 49 11.4 14.6 2 40 3 — — 23.5
South Korea KMIC 1992 160,242 44.0 33 7.7 4.0 38 58 0 — — 23.0
Taiwan CVDFACTS 1988-1996 5,729 47.2 55 2.7 6.0 1 48 1 — — 23.5
Asia Subtotal 1961-1998 420,310 44.6 33 6.6 6.5 174 59 5 16 11 22.8
Total 1961-1999 519,643 46.3 35 6.2 6.8 324 53 7 17 15 23.7
NOTE: Blank denotes no data available.
Abbreviations: NZ, New Zealand; CPD, cigarettes per day for current smokers; M, males; F, females; PC, pancreatic cancer.
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residual confounding by consumption of alcohol due to a lack
of information on alcohol intake within the Asia Pacific Cohort
Studies Collaboration. However, several prospective studies
have reported that adjustment for alcohol did not materially
attenuate the association between smoking and pancreatic
cancer (4, 32).
A relationship between type 2 diabetes and mortality from
pancreatic cancer has been consistently reported in the
literature. The current finding of an approximate 80% increase
in risk is in line with findings from a recent meta-analysis that
concluded that type 2 diabetes is associated with an f2-fold
increase in risk of the neoplasm (3). Further support for a
causal association between diabetes and mortality from
pancreatic cancer is provided by evidence of a dose-response
association in the current study that is supported by findings
from other large prospective studies (33-35).
Table 2. HRs and 95% CIs for the associations between known and putative risk factors and mortality from pancreatic
cancer
Covariate No.
subjects
No.
deaths
Adjusted for age, sex
and study HR (95% CI)
Multiple-adjusted
HR (95% CI)
Cigarettes per day
Nonsmoking* 59,387 84 1 1
c
<20 8,690 14 1.17 (0.64-2.13) 1.17 (0.64-2.13)
z20 9,242 26 1.86 (1.09-3.17) 1.86 (1.09-3.17)
Fasting blood glucose (mmol/L)
<5.2* 125,855 28 1 1
b
5.2-5.78 41,118 28 1.75 (1.01-3.04) 1.79 (1.03-3.10)
z5.79 27,041 29 1.96 (1.12-3.44) 2.08 (1.18-3.67)
BMI (kg/m2)
<23* 121,714 77 1 1x
23-26 110,408 76 1.03 (0.74-1.45) 1.07 (0.76-1.49)
z26 74,093 77 0.98 (0.68-1.42) 1.00 (0.69-1.45)
Height (cm)
V159* 84,806 73 1 1x
160-170 142,524 74 0.71 (0.48-1.06) 0.71 (0.48-1.06)
z171 74,568 69 1.17 (0.71-1.93) 1.21 (0.74-1.98)
Total cholesterol (mmol/L)
<4.8* 105,749 68 1 1k
4.8-5.7 108,609 72 0.87 (0.61-1.22) 0.87 (0.61-1.23)
z5.8 69,465 68 0.74 (0.50-1.08) 0.73 (0.50-1.07)
Systolic blood pressure (mm Hg)
<130* 200,311 81 1 1k
131-146 59,093 70 1.33 (0.95-1.86) 1.34 (0.96-1.87)
z147 46,807 79 1.19 (0.84-1.69) 1.20 (0.84-1.71)
Diastolic blood pressure (mm Hg)
<76* 129,210 82 1 1k
76-86 107,068 74 0.85 (0.61-1.17) 0.85 (0.62-1.18)
z87 69,933 74 0.94 (0.67-1.31) 0.95 (0.68-1.33)
*Reference group.
cAdjusted for diabetes and BMI.
bAdjusted for smoking and BMI.
xAdjusted for smoking and diabetes.
kAdjusted for smoking, diabetes and BMI.
Figure 1. Multiple-adjusted HRs
and 95% CIs for the associations
between known and putative risk
factors for mortality from pancreat-
ic cancer in men and women from
Asia and ANZ.
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In a recent meta-analysis, obesity was weakly associated
with an increased risk of pancreatic cancer (7), but findings
from the current study for such an association were unequiv-
ocally null. BMI, however, is a crude measure of adiposity and
provides no information regarding the distribution of body fat,
which may be more predictive of risk. Central adiposity is
strongly correlated with intra-abdominal fat and with in-
creased insulin secretion and insulin resistance. Such distur-
bances in insulin metabolism are suggested to have a
carcinogenic effect (36). In the current study, waist circumfer-
ence, which is a measure of central obesity, was significantly
and positively associated with pancreatic cancer, in agreement
with the findings of Larsson et al. (5). Similarly, data from the
European Prospective Investigation into Cancer and Nutrition
study also reported that, in contrast to BMI that showed no
association, central adiposity was positively associated with
the incidence of pancreatic cancer (37). Moreover, in the
current analyses, the relationship between central adiposity
and mortality from pancreatic cancer was not confounded by
diabetes; as such, adjustment did not have any material effect
on the association. Our finding of a weak positive association
between height and pancreatic cancer is in agreement with
some (36, 38), but not all (39-41), previous reports. In the
European Prospective Investigation into Cancer and Nutrition
study, height was shown to be positively associated with
pancreatic cancer, although the relationship was driven by a
low risk in the lowest quartile of the height distribution (37).
Therefore, it remains to be determined whether height is an
important risk factor for the neoplasm.
Previous studies have suggested positive associations
between hypertension and the use of antihypertensive medi-
cation, such as diuretics and calcium-channel blockers in
particular, and risk of cancer (42-45). We found no evidence to
suggest an association with blood pressure, but there was
some evidence to suggest a 50% greater risk of mortality from
pancreatic cancer among those prescribed, blood pressure–
lowering medications. However, data from large blood
pressure–lowering trials, including PROGRESS (46), reported
no excess risk of all-cause cancer among individuals pre-
scribed more intensive, versus less intensive, regimes of
antihypertensive medication. Moreover, data from ALLHAT
(47) showed that calcium channel blockers were not associated
with an increased risk of cancer compared with other blood
pressure–lowering medications. It is possible that our finding
of an increased risk of pancreatic cancer with antihypertensive
medication is a chance finding due to bias, particularly
survivor bias, that is those individuals not prescribed blood
pressure–lowering treatment died from cardiovascular dis-
ease before they contracted cancer. Alternatively, it may be an
artifact due to the fact that individuals receiving treatment for
hypertension may be more likely to have had their pancreatic
cancer diagnosed compared with untreated hypertensives who
may not have received regular medical check-ups.
The literature contains some reports (11-13) of an inverse
association between blood cholesterol and increased risk of
cancer, specifically of the lung and liver, although data from
the current analysis do not lend strong support to this
hypothesis in agreement with findings from a large Finnish
study that reported no association between either total or high-
density lipoprotein cholesterol with pancreatic cancer (48).
Moreover, evidence from large randomized trials of cholester-
ol-lowering agents, such as the Heart Protection Study (49), do
not support a greater risk of cancer among subjects receiving
cholesterol medication compared with those who do not,
although the shorter length of follow-up in such studies
(<5 yrs) makes it impossible to examine the long-term effect of
treatment. Hence, it remains unclear whether a low cholesterol
level is, indeed, a risk factor for certain cancers.
In addition to the lack of information on duration of
smoking, age of smoking uptake, and the inability to
discriminate between type 1 and type 2 diabetes, all of which
may have diluted the strength of the observed associations,
there are several other limitations that warrant discussion. The
analyses were based on self-reported cigarette consumption,
which may have introduced bias. In addition, measurement
error may have been present especially for waist circumfer-
ence, which is more difficult to reliably measure than either
weight or height. Finally, the individual studies used different
methods to verify mortality from pancreatic cancer, whereas
the methods used will also have varied over time. The lack of
standardization could have had some unpredictable effect on
the results.
To our knowledge, this is the first study to evaluate the
population attributable risks of smoking and diabetes on
mortality from pancreatic cancer among men from two
populations of the Asia-Pacific region. The coexistence of
these two modifiable risk factors conferred a more than
doubling of risk of mortality from pancreatic cancer compared
with men in whom such risk factors were absent. Cigarette
smoking and diabetes explained a significant proportion of
pancreatic cancer in both China and Australian, which
suggests that interventions that reduce the prevalence of
smoking and diabetes, together with those targeting obesity,
would have a substantial effect on reducing mortality from a
wide spectrum of chronic diseases, including pancreatic cancer
in both Asian and non-Asian populations.
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Welborn; Beijing Aging : Z. Tang; Beijing Steelworkers : L.S. Liu,
J.X. Xie; Blood Donors’ Health: R. Norton, S. Ameratunga,
S. MacMahon, G. Whitlock; Busselton : M.W. Knuiman;
Canberra-Queanbeyan: H. Christensen; Capital Iron and Steel
Company Hospital Cohort: J. Zhou, X.H. Yu; Capital Iron and
Steel Company : X.G. Wu; Civil Service Workers : A. Tamakoshi;
CVDFACTS : W.H. Pan; Electricity Generating Authority of
Thailand : P. Sritara; East Beijing : Z.L. Wu, L.Q. Chen, G.L.
Shan; Fangshan Farmers : D.F. Gu, X.F. Duan; Fletcher Challenge:
S. MacMahon, R. Norton, G. Whitlock, R. Jackson; Guangzhou :
Y.H. Li; Guangzhou Occupational : T.H. Lam, C.Q. Jiang;
Hisayama : M. Fujishima, Y. Kiyohara, H. Iwamoto; Hong Kong :
J. Woo, S.C. Ho; Huashan : Z. Hong, M.S. Huang, B. Zhou;
Table 3. Population attributable fractions for mortality
from pancreatic cancer due to cigarette smoking and
diabetes in China and Australia
Population attributable risk (%)
China Australia
Men Women Men Women
Cigarette smoking 35 2 14 9
Diabetes 3 2 8 5
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Kinmen : J.L. Fuh; Kounan Town : H. Ueshima, Y. Kita, S.R.
Choudhury; Korean Medical Insurance Company : I. Suh, S.H. Jee,
I.S. Kim; Melbourne Cohort : G. Giles; Miyama : T. Hashimoto, K.
Sakata; Newcastle : A. Dobson; Ohasama : Y. Imai, T. Ohkubo,
A. Hozawa; Perth : K. Jamrozik, M. Hobbs, R. Broadhurst;
Saitama : K. Nakachi; Seven Cities : X.H. Fang, S.C. Li, Q.D.
Yang; Shanghai Factory Workers : Z.M. Chen; Shibata : H. Tanaka;
Shigaraki : Y. Kita, A. Nozaki, H. Ueshima; Shirakawa : H.
Horibe, Y. Matsutani, M. Kagaya; Singapore Heart : K. Hughes,
J. Lee; Singapore 92 : D. Heng, S.K. Chew; Six Cohorts : B.F. Zhou,
H.Y. Zhang; Tanno/Soubetsu : K. Shimamoto, S. Saitoh; Tianjin :
Z.Z. Li, H.Y. Zhang; Western Australian AAA Screenees:
P. Norman, K. Jamrozik; Xi’an : Y. He, T.H. Lam; Yunnan :
S.X. Yao. (Note: The studies in italics contributed data to these
analyses).
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